The One Thing You Need to Know About Eli Lilly

With so many drugs in different stages of development, one single product rarely defines an entire drugmaker. Merck (NYSE: MRK  ) lost Vioxx and kept on ticking; GlaxoSmithKline's (NYSE: GSK  ) Avandia is all but dead, but it won't break the company.

Somehow, things aren't working out that way for Eli Lilly (NYSE: LLY  ) . The company managed to line up a whole mess of blockbusters that will see patent expirations in a very short window of time.

Drug

2009 Sales (in billions)

Patent Expires

Zyprexa

$4.9

2011

Gemzar

$1.4

2013*

Humalog

$2.0

2013

Cymbalta

$3.1

2013

Source: Company 10-K. *May be Nov. 2010 if current court decisions hold.

This means that you basically have to throw out any valuation metric that involves trailing data. Price/earnings, price/sales, and price/free cash flow ratios all make the company look cheap, but none of them are really relevant when sales, earnings, and cash flow are sure to fall after generics hit the market. Even the dividend yield is up in the air. The company has plenty of cash to cover it now, but down the line, we could very well see a cut to the dividend.

The solution, of course, is to bring more drugs on the market to make up for those going off-patent -- but that's easier said than done. Eli Lilly does have quite a few compounds in clinical trials, but most are in the early stage. Management was out in full force this week, touting the prospects of buying its way to a beefed-up pipeline.

I like the idea of buying in bits and pieces, rather than making a major purchase like Pfizer (NYSE: PFE  ) and Merck did. Licensing drugs also allows you to pin some of the risk back on the inventor through milestone payments tied to FDA approvals or even sales. But it's not like every drug is a blockbuster. How many purchases must Lilly make to replace its multibillion-dollar drugs?

If the patent cliff is the one thing you need to know about, the additions to the pipeline are the one thing you need to watch going forward.

Matt Koppenheffer urges you not to listen to stock market stupidity.

Pfizer is a Motley Fool Inside Value selection. GlaxoSmithKline is a Motley Fool Global Gains recommendation. Try any of our Foolish newsletter services free for 30 days.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool owns shares of GlaxoSmithKline and has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1317367, ~/Articles/ArticleHandler.aspx, 10/21/2014 4:13:04 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement